Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

View original at seekingalpha.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • About one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range

    60% confidence
  • Up to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)

    60% confidence
  • Retatrutide reduced knee osteoarthritis pain scores by as much as 73%

    60% confidence
  • More than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity

    60% confidence
  • In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks

    60% confidence
  • Discontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level

    60% confidence
  • GLP-1 drug market sales forecast raised to $150 billion

    60% confidence
  • Among more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)

    60% confidence
  • Highest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end

    60% confidence
  • Retatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies

    60% confidence
  • In TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%

    60% confidence
  • Retatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide — Source | Via News | ViaNews Market